1. Department of Immunology, Laboratory for Medical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands;
2. Department of Hematology, University of Schleswig-Holstein, Kiel, Germany;
3. Oncogeriatric Unit, Department of Geriatric Medicine, St. Marien Hospital, Cologne, Germany;
4. German CLL Study Group, Department I of Internal Medicine and Center of Integrated Oncology Cologne Bonn, University Hospital of Cologne, Cologne, Germany;
5. Division of Hematology and Oncology, Medical University of Innsbruck, Innsbruck, Austria;
6. Charles University Hospital, Prague, Czech Republic;
7. Royal North Shore Hospital, University of Sydney, Sydney, Australia;
8. Kantonsspital Graubünden, Chur, Switzerland;
9. Pharma Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland;
10. Pharma Development Oncology, Roche Products Ltd, Welwyn, United Kingdom;
11. Internal Medicine III, University of Ulm, Ulm, Germany;
12. Clinic III, Hematology, Oncology and Palliative Medicine, University of Rostock, Rostock, Germany;
13. Cologne Center of Excellence for Cellular Stress Response and Aging Related Diseases, University of Cologne, Cologne, Germany; and
14. Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands